Cefadroxil

Summary

Cefadroxil (CHEMBL1644) is an approved small-molecule antibacterial drug (ATC J01DB05); indicated across 4 conditions including bacterial infectious disease and pharyngitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DB05
• Indications: 4 conditions
• Clinical trials: 9
• Chemistry: 363.4 Da · C16H17N3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1644
Name	Cefadroxil
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	47965
ChEBI	CHEBI:3479
ATC	J01DB05
Molecular formula	C16H17N3O5S
Molecular weight	363.4
InChIKey	BOEGTKLJZSQCCD-UEKVPHQBSA-N

SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O

IUPAC name: (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Anhydrous cefadroxil, Baxan, BL-S578, Cefadroxil, Cefadroxil (as monohydrate), Cefadroxil anhydrous, Cefadroxil hydrate, Cefadroxil monohydrate, Cefadroxil/cefadroxil hemihydrate, Cefadroxilo, Cefadrops, Cefatabs

Patent coverage: 1,817 distinct patent families (6,102 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Solute carrier family 22 member 6, Organic anion transporter 3, Solute carrier family 15 member 2, Estrogen receptor, Glutamate receptor ionotropic, NMDA 1, Solute carrier family 15 member 2.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC15A2	5.6	Ki	2500	nM	CHEMBL_ACT_11002757
SLC15A2	5.55	Ki	2800	nM	CHEMBL_ACT_11002765
Q63424	5.52	Ki	3000	nM	CHEMBL_ACT_11003103
Q63424	5.52	Ki	3000	nM	CHEMBL_ACT_11003104
SLC15A2	5.52	Ki	3000	nM	CHEMBL_ACT_6307771
SLC15A2	5.52	Ki	3020	nM	CHEMBL_ACT_6307845
SLC22A6	5.21	Ki	6140	nM	CHEMBL_ACT_11003210
SLC22A8	5.06	Ki	8620	nM	CHEMBL_ACT_11003289
SLC22A8	5.06	Ki	8620	nM	CHEMBL_ACT_15445017

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
pharyngitis	4	MONDO:0002258	MONDO:0002258
pulmonary tuberculosis	2	MONDO:0006052	EFO:1000049

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	2
PHASE2	2
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04297592	PHASE4	ENROLLING_BY_INVITATION	Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
NCT05977868	PHASE4	TERMINATED	Comparing Oral Versus Parenteral Antimicrobial Therapy
NCT02814916	PHASE3	COMPLETED	Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
NCT04723940	PHASE3	UNKNOWN	Or v IV Antibiotics for Infection
NCT06406114	PHASE2	RECRUITING	Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT02381470	PHASE2	COMPLETED	Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
NCT02479867	PHASE1	COMPLETED	A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)
NCT03802552	PHASE1	COMPLETED	Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
NCT00405158	Not specified	COMPLETED	Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).